<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2f2fccc5-9cbf-27d6-e063-6294a90a55f9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use POTASSIUM PHOSPHATES INJECTION safely and effectively. See full prescribing information for POTASSIUM PHOSPHATES INJECTION.POTASSIUM PHOSPHATES injection, for intravenous useInitial U.S. Approval: 1983</title>
   <effectiveTime value="20250228"/>
   <setId root="f1f26a17-d2e2-48f5-9054-8ee7e380556e"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="078719707"/>
            <name>Cipla USA Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="650138746"/>
                  <name>Cipla Limited</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="876894109"/>
                        <name>ABRYL LABORATORIES PRIVATE LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69097-078" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69097-077" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69097-055" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2f2fe4e8-e799-42d5-e063-6294a90a56df"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69097-078" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium Phosphates</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Phosphates</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N762921K75" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="224"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4J9FJ0HL51" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MONOBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="236"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI71S98N1Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69097-078-67" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="69097-078-97" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250206"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217892" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250206"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69097-077" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium Phosphates</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Phosphates</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N762921K75" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="224"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4J9FJ0HL51" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MONOBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="236"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI71S98N1Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69097-077-67" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="69097-077-97" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250206"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217892" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250206"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69097-055" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium Phosphates</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Phosphates</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N762921K75" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="224"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4J9FJ0HL51" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MONOBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="236"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="CI71S98N1Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC POTASSIUM PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69097-055-67" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="25" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="69097-055-97" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250206"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA217892" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250206"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S-2b34a196-cfee-46ee-b332-7509860c4b80">
               <id root="2f2fccc5-9cc0-27d6-e063-6294a90a55f9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Potassium phosphates injection is indicated as a source of phosphorus:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.</item>
                     <item>for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated.</item>
                  </list>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20240926"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potassium phosphates injection is a phosphorus replacement product indicated as a source of phosphorus:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-2b34a196-cfee-46ee-b332-7509860c4b80">1</linkHtml>
                              </content>)
 
    </item>
                           <item>for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-2b34a196-cfee-46ee-b332-7509860c4b80">1</linkHtml>
                              </content>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cc1-27d6-e063-6294a90a55f9"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer intravenously only after dilution or admixing in a larger volume of fluid. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>)
 
    </item>
                           <item>Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>)
 
    </item>
                           <item>Monitor serum phosphorus, potassium, calcium, and magnesium concentrations. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>)
 
    </item>
                           <item>See full prescribing information for instructions on preparation and administration. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                              </content>)
 
    </item>
                        </list>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage for Correction of Hypophosphatemia in Intravenous Fluids</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Potassium phosphates injection is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL; otherwise, use an alternative source of phosphorus. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>)
 
    </item>
                           <item>The dosage is dependent upon the individual needs of the patient, and the contribution of phosphorus and potassium from other sources. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>)
 
    </item>
                           <item>See full prescribing information for recommendations on initial or single dosing, repeated dosing, concentration and infusion rate. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>)
 
    </item>
                        </list>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage for Administration in Parenteral Nutrition</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Individualize the dosage based upon the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral phosphorus and potassium intake. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>)
 
    </item>
                           <item>See full prescribing information for recommendations for daily and maximum dosage. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S-cb6756f5-df6a-4baf-862a-70734970cc84">
                     <id root="2f2fccc5-9cc2-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Preparation and Administration in Intravenous Fluids to Correct Hypophosphatemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Preparation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Potassium phosphates injection is for
  
   <content styleCode="italics">intravenous infusion</content>into a central or peripheral vein
  
   <content styleCode="italics">only after dilution</content>.
 
  </item>
                           <item>Using aseptic technique, withdraw the required amount from the vial and add to 0.9% Sodium Chloride Injection, USP (normal saline) or 5% Dextrose Injection, USP (D5W). For adults and pediatric patients 12 years of age and older a total volume of 100 mL or 250 mL is recommended. For pediatric patients less than 12 years of age, use the smallest recommended volume, considering daily fluid requirements and the maximum concentration for peripheral and central administration shown in Table 1.</item>
                           <item>The concentration of the diluted solution should take into consideration the age of the patient, the amounts of phosphorus and potassium in the dose, and is dependent upon whether administration will be through a peripheral or central venous catheter. The recommended maximum concentrations are shown in Table 1:</item>
                        </list>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 1: Maximum Recommended Concentration of Potassium Phosphates Injection by Age and Route of Administration (Peripheral vs. Central)</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <table width="100%">
                           <col width="34%" align="left" valign="middle"/>
                           <col width="33%" align="left" valign="middle"/>
                           <col width="33%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <td align="center">
                                    <paragraph>Patient Population</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>Peripheral Venous Catheter</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>Central Venous Catheter</paragraph>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>Adults and Pediatric Patients 12 Years of Age and Older</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>phosphorus 6.8 mmol/100 mL (potassium 10 mEq/100 mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>phosphorus 18 mmol/100 mL (potassium 26.4 mEq/100 mL)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule">
                                    <paragraph>Pediatric Patients Less than 12 Years of Age</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>phosphorus 0.27 mmol/10 mL (potassium 0.4 mEq/10 mL)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>phosphorus 0.55 mmol/10 mL (potassium 0.8 mEq/10 mL)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Visually inspect the solution for particulate matter and discoloration before and after dilution and prior to administration. Do not administer unless solution is clear, and seal on the vial is intact.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Check serum potassium and calcium concentrations prior to administration. Normalize the calcium before administering potassium phosphates injection
  
   <content styleCode="italics">[see Contraindications (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>
                              <content styleCode="italics">), Warnings and Precautions (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                              </content>
                              <content styleCode="italics">,</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.
 
  </item>
                           <item>Potassium phosphates injection is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>. If the potassium concentration is 4 mEq/dL or more, use an alternative source of phosphorus.
 
  </item>
                           <item>Do not infuse with calcium-containing intravenous fluids
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.
 
  </item>
                           <item>The rate of administration may be dependent on the patient and the specific institution policy
  
   <content styleCode="italics">[see Dosage and Administration (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.
 
  </item>
                        </list>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Storage and Stability</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Single
  
   <content styleCode="italics">-Dose Vial (5 mL and 15 mL)</content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Circle">
                           <item>For single use only. Discard used vial, including any unused contents.</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pharmacy
  
   <content styleCode="italics">Bulk Package Vial (50 mL)</content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Circle">
                           <item>Penetrate vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents.</item>
                           <item>Use potassium phosphates injection promptly once the sterile transfer set has been inserted into the Pharmacy Bulk Package vial or a maximum of 4 hours at room temperature 20°C to 25°C (68°F to 77°F) after the container closure has been penetrated. Discard any remaining drug.</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>After dilution, the solution is stable for a maximum of 4 hours at room temperature 20°C to 25°C (68°F to 77°F) or 14 days under refrigeration at 2°C to 8°C (36°F to 46°F).</item>
                        </list>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="S-784b8156-9e6d-4bb0-a47b-d4df152bc237">
                     <id root="2f2fccc5-9cc3-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage for Administration in Intravenous Fluids to Correct Hypophosphatemia</title>
                     <text>
                        <paragraph>Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). </paragraph>
                        <paragraph>The dosage is dependent upon the individual needs of the patient, and the contribution of phosphorus and potassium from other sources.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Initial or Single Dose</content>
                        </paragraph>
                        <paragraph>The phosphorus doses in Table 2 are general recommendations for an initial or single dose and are intended for most patients. Based upon clinical requirements, some patients may require a lower or higher dose. The maximum initial or single dose of phosphorus is 45 mmol (potassium 66 mEq)
 
  <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-73dc1c12-6aaf-4223-8218-5af3789dbd57">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph>In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m2 to &lt;60 mL/min/1.73 m2), start at the low end of the dose range
 
  <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-001a9f01-9249-421f-a4e8-02dcc60d5fcc">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph>Monitor serum phosphorus, potassium, calcium and magnesium serum concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 2: Recommended Initial or Single Dose of Potassium Phosphates Injection in Intravenous Fluids to Correct Hypophosphatemia in Adults and Pediatric Patients</content>
                        </paragraph>
                        <table width="100%">
                           <col width="34%" align="left" valign="middle"/>
                           <col width="33%" align="left" valign="middle"/>
                           <col width="33%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <td align="center">
                                    <paragraph>Serum Phosphorus Concentration
     
      <sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>Phosphorus Dosage
     
      <sup>b, c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>Corresponding Potassium Content</paragraph>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>1.8 mg/dL to lower end of the reference range
     
      <sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>0.16 mmol/kg to 0.31 mmol/kg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>potassium 0.23 mEq/kg to 0.46 mEq/kg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule">
                                    <paragraph>1 mg/dL to 1.7 mg/dL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>0.32 mmol/kg to 0.43 mmol/kg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>potassium 0.47 mEq/kg to 0.63 mEq/kg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule">
                                    <paragraph>Less than 1 mg/dL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>0.44 mmol/kg to 0.64 mmol/kg
     
      <sup>c</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>potassium 0.64 mEq/kg to 0.94 mEq/kg</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup> </sup>
                           <sup> </sup>
                           <sup>a</sup>Serum phosphorus reported using 2.5 mg/dL as the lower end of the reference range for healthy adults and pediatric patients 12 months of age and older. Serum phosphorus reported using 4 mg/dL as the lower end of the reference range for preterm and term infants less than 12 months of age. Serum phosphorus concentrations may vary depending on the assay used and the laboratory reference range.

 </paragraph>
                        <paragraph>
                           <sup> </sup>
                           <sup> </sup>
                           <sup>b</sup>Weight is in terms of actual body weight. Limited information is available regarding dosing of patients significantly above ideal body weight; consider using an adjusted body weight for these patients.

 </paragraph>
                        <paragraph>
                           <sup> </sup>
                           <sup> </sup>
                           <sup>c</sup>up to a maximum of phosphorus 45 mmol (potassium 66 mEq) as a single dose.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Concentration and Intravenous Infusion Rate</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The concentration of the diluted solution
  
   <content styleCode="italics">[see Table 1, Dosage and Administration (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>and the infusion rate is dependent upon whether administration will be through a peripheral or central venous catheter. The maximum recommended infusion rates are shown in Table 3 for adults and pediatric patients 12 years of age and older.
 
  </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">TABLE 3: Maximum Recommended Infusion Rate of Potassium Phosphates Injection for Adults and Pediatric Patients 12 Years of Age and Older</content>
                        </paragraph>
                        <table width="100%">
                           <col width="50%" align="left" valign="middle"/>
                           <col width="50%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Route of Administration</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>
                                       <content styleCode="bold">Maximum Infusion Rate</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>Peripheral Venous Catheter</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule Rrule Botrule">
                                    <paragraph>phosphorus 6.8 mmol/hour (potassium 10 mEq/hour)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule">
                                    <paragraph>Central Venous Catheter</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule">
                                    <paragraph>phosphorus 15 mmol/hour (potassium 22 mEq/hour)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Continuous electrocardiographic (ECG) monitoring and infusion through a central venous catheter is recommended for infusion rates higher than:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Potassium 10 mEq/hour for adults and pediatric patients weighing 20 kg or greater</item>
                           <item>Potassium 0.5 mEq/kg/hour for pediatric patients weighing less than 20 kg</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Repeated Dosing</content>
                        </paragraph>
                        <paragraph>Additional dose(s) following the initial dose may be needed in some patients. Prior to administration of additional doses, assess the patient clinically, obtain serum phosphorus, calcium and potassium concentrations and adjust the dose accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20240926"/>
                  </section>
               </component>
               <component>
                  <section ID="S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">
                     <id root="2f2fccc5-9cc4-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation and Administration in Parenteral Nutrition</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Potassium phosphates injection is for
  
   <content styleCode="italics">intravenous infusion</content>into a peripheral or central vein
  
   <content styleCode="italics">only after dilution</content>and
  
   <content styleCode="italics">admixing</content>.
 
  </item>
                           <item>Potassium phosphates injection is to be prepared only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). The key factor in the preparation is careful aseptic technique to avoid inadvertent touch contamination during mixing of solutions and addition of other nutrients.</item>
                           <item>Transfer the required amount of potassium phosphates injection to the parenteral nutrition solution following the admixture of amino acids, dextrose, electrolytes solutions, and prior to lipids (if added).</item>
                           <item>Because additives may be incompatible, evaluate all additions to the parenteral nutrition container for compatibility and stability of the resulting preparation.</item>
                           <item>Calcium and phosphate ratios must be considered. Excess addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of calcium-phosphate precipitates
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-0294bce5-bdcc-4561-9222-0a43de548eb4">5.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>. Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. Discard if any precipitates are observed.
 
  </item>
                           <item>Inspect the final parenteral solution containing potassium phosphates injection to ensure that:</item>
                        </list>
                        <list listType="unordered" styleCode="Circle">
                           <item>precipitates have not formed during mixing or addition of additives and inspect again before administration.</item>
                           <item>the emulsion has not separated, if lipids have been added. Separation of the emulsion can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion.</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>The final parenteral nutrition solution is for intravenous infusion into a peripheral or central vein. The choice of a peripheral or central venous route should depend on the osmolarity of the final infusate. Solutions with osmolarity of 900 mOsmol/L or greater must be infused through a central catheter
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                              <content styleCode="underline">
                                 <linkHtml href="#S-db81a30d-d481-4bf5-b388-cfb7f91a0685">5.7</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>.
 
  </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Protect the parenteral nutrition solution from light during storage.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Stability</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Single-Dose Vial (5 mL and 15 mL)</content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Circle">
                           <item>For single use only. Discard used vial, including any unused contents.</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Pharmacy Bulk Package Vial (50 mL)</content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="Circle">
                           <item>Penetrate vial closure only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents.</item>
                           <item>Use potassium phosphates injection for admixing promptly once the sterile transfer set has been inserted into the Pharmacy Bulk Package vial or a maximum of 4 hours at room temperature 20°C to 25°C (68°F to 77°F) after the container closure has been penetrated. Discard any remaining drug.</item>
                        </list>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use parenteral nutrition solution containing potassium phosphates injection promptly after mixing. Any storage of the admixture should be under refrigeration from 2°C to 8°C (36°F to 46°F) and limited to a brief period of time, no longer than 24 hours. After removal from refrigeration, bring to room temperature and use promptly and complete the infusion within 24 hours. Discard any remaining admixture.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240927"/>
                  </section>
               </component>
               <component>
                  <section ID="S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">
                     <id root="2f2fccc5-9cc5-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage for Administration in Parenteral Nutrition</title>
                     <text>
                        <paragraph>Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL).</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>The recommended daily dosage in parenteral nutrition is shown in Table 4. Individualize the dosage based upon the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral phosphorus and potassium intake. The amount of phosphorus that can be added to parenteral nutrition may be limited by the amount of calcium that is also added to the solution.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="bold">TABLE 4: Recommended Daily Dosage of Potassium Phosphates Injection for Parenteral Nutrition for Adults and Pediatric Patients</content>
                        </paragraph>
                        <table width="100%">
                           <col width="50%" align="left" valign="middle"/>
                           <col width="50%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Patient Population</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Generally Recommended Phosphorus Daily Dosage (Potassium Content)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                                    <paragraph>Preterm and Term Infants Less than 12 Months</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule Toprule">
                                    <paragraph>2 mmol/kg/day (potassium 2.9 mEq/kg/day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule">
                                    <paragraph>Pediatric Patients 1 year to Less Than 12 years</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule">
                                    <paragraph>1 mmol/kg/day; up to 40 mmol/day (potassium 1.5 mEq/kg/day; up to 58.7 mEq/day)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule Lrule Rrule">
                                    <paragraph>Adults and Pediatric Patients 12 Years of Age and Older</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Rrule">
                                    <paragraph>20 mmol/day to 40 mmol/day
     
      <sup>a</sup>(potassium 29.3 mEq/day to 58.7 mEq/day)
    
     </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m
 
  <sup>2</sup>to &lt;60 mL/min/1.73 m
 
  <sup>2</sup>), start at the low end of the dosage range.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Monitoring</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Monitor serum phosphorus, potassium, calcium and magnesium concentrations and adjust the dosage accordingly.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S-aa306c70-1922-4053-8338-47cdcf112e2f">
               <id root="2f2fccc5-9cc6-27d6-e063-6294a90a55f9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Potassium phosphates injection, USP is a clear and colorless solution free from visible particulates supplied as:</paragraph>
                  <paragraph> </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>phosphorus 15 mmol/5 mL (3 mmol/mL) and potassium 22 mEq/5 mL (4.4 mEq /mL) in a single-dose vial.</item>
                     <item>phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 66 mEq/15 mL (4.4 mEq/mL) in a single-dose vial.</item>
                     <item>phosphorus 150 mmol/50 mL (3 mmol/mL) and potassium 220 mEq/50 mL (4.4 mEq/mL) in Pharmacy Bulk Package vial.</item>
                  </list>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20240320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>  Injection:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>phosphorus 15 mmol/5 mL (3 mmol/mL) and potassium 22 mEq/5 mL (4.4 mEq/mL) in a single-dose vial. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-aa306c70-1922-4053-8338-47cdcf112e2f">3</linkHtml>
                              </content>)
 
    </item>
                           <item>phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 66 mEq/15 mL (4.4 mEq/mL) in a single-dose vial. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-aa306c70-1922-4053-8338-47cdcf112e2f">3</linkHtml>
                              </content>)
 
    </item>
                           <item>phosphorus 150 mmol/50 mL (3 mmol/mL) and potassium 220 mEq/50 mL (4.4 mEq/mL) as a Pharmacy Bulk Package vial.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S-8385e99f-76fd-4089-890c-4e88f26a7f5d">
               <id root="2f2fccc5-9cc7-27d6-e063-6294a90a55f9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Potassium phosphates injection is contraindicated in patients with:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>hyperkalemia
  
   <content styleCode="italics">[see Warning and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>severe renal impairment (eGFR less than 30 mL/min/1.73m2) or end stage renal disease
  
   <content styleCode="italics">[see Warning and Precautions (</content>
                        <content styleCode="italics">
                           <content styleCode="underline">
                              <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                           </content>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>hyperphosphatemia
  
   <content styleCode="italics">[see Warning and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>hypercalcemia or significant hypocalcemia
  
   <content styleCode="italics">[see Warning and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240910"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>hyperkalemia (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>)
 
    </item>
                           <item>hyperphosphatemia (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>)
 
    </item>
                           <item>hypercalcemia or significant hypocalcemia (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>)
 
    </item>
                           <item>severe renal impairment (eGFR less than 30 mL/min/1.73m
  
     <sup>2</sup>) or end stage renal disease (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cc8-27d6-e063-6294a90a55f9"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240927"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Serious Cardiac Adverse Reactions with Undiluted, Bolus, or Rapid Intravenous Administration</content>: Administer only after dilution or admixing; do not exceed the recommended infusion rate. Continuous electrocardiographic (ECG) monitoring may be needed during infusion. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-73dc1c12-6aaf-4223-8218-5af3789dbd57">5.1</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Pulmonary Embolism due to Pulmonary Vascular Precipitates</content>: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-0294bce5-bdcc-4561-9222-0a43de548eb4">5.2</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Hyperkalemia</content>: Increased risk in patients with renal impairment, severe adrenal insufficiency, or treated with drugs that increase potassium. Patients with cardiac disease may be more susceptible. Do not exceed the maximum daily amount of potassium or the recommended infusion rate. Continuous ECG monitoring may be needed during infusion. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-fb62b24f-b83d-4510-9e5d-4a48f8eb0317">7.1</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Hyperphosphatemia and Hypocalcemia</content>: Monitor serum phosphorus and calcium concentrations during and following infusion. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Aluminum Toxicity</content>: Increased risk in patients with renal impairment, including preterm infants. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-67628c11-497b-4043-8969-f7b215936495">8.4</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Hypomagnesemia</content>: Reported in patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-db40c10b-c739-459c-b631-d6b693ca1493">5.6</linkHtml>
                              </content>)
 
    </item>
                           <item>
                              <content styleCode="underline">Vein Damage and Thrombosis</content>: Infuse concentrated or hypertonic solutions through a central catheter. (
  
     <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                              </content>,
  
     <content styleCode="underline">
                                 <linkHtml href="#S-db81a30d-d481-4bf5-b388-cfb7f91a0685">5.7</linkHtml>
                              </content>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S-73dc1c12-6aaf-4223-8218-5af3789dbd57">
                     <id root="2f2fccc5-9cc9-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Serious Cardiac Adverse Reactions with Undiluted, Bolus or Rapid Intravenous Administration</title>
                     <text>
                        <paragraph>Intravenous administration of potassium phosphates to correct hypophosphatemia in single doses of phosphorus 50 mmol and greater and/or at rapid infusion rates (over 1 to 3 hours) in intravenous fluids has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia, and seizures
 
  <content styleCode="italics">[see Overdosage (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-54791af5-2013-4580-aec1-67ae6ad5bd1c">10</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)].</content>In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid “IV push” has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Potassium phosphates injection is for
 
  <content styleCode="italics">intravenous infusion only after dilution or admixing</content>. The maximum initial or single dose of potassium phosphates injection in intravenous fluids to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate for administration through a peripheral venous catheter is approximately phosphorus 6.8 mmol/hour (potassium 10 mEq/hour). Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
               <component>
                  <section ID="S-0294bce5-bdcc-4561-9222-0a43de548eb4">
                     <id root="2f2fccc5-9cca-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Pulmonary Embolism due to Pulmonary Vascular Precipitates</title>
                     <text>
                        <paragraph>Pulmonary vascular emboli and pulmonary distress related to precipitates in the pulmonary vasculature have been described in patients receiving admixed products containing calcium and phosphate or parenteral nutrition. The cause of precipitate formation has not been determined in all cases; however, in some fatal cases, pulmonary emboli occurred as a result of calcium phosphate precipitates. Precipitation has occurred following passage through an in-line filter;
 
  <content styleCode="italics">in vivo</content>precipitate formation may also have occurred. If signs of pulmonary distress occur, stop the parenteral nutrition infusion and initiate a medical evaluation. In addition to inspection of the solution
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>, the infusion set and catheter should also periodically be checked for precipitates.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
               <component>
                  <section ID="S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">
                     <id root="2f2fccc5-9ccb-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hyperkalemia</title>
                     <text>
                        <paragraph>Potassium phosphates injection may increase the risk of hyperkalemia, including life-threatening cardiac events, especially when administered in excessive doses, undiluted or by rapid intravenous infusion
 
  <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-73dc1c12-6aaf-4223-8218-5af3789dbd57">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Patients with severe renal impairment and end stage renal disease are at increased risk of developing life-threatening hyperkalemia, when administered intravenous potassium
 
  <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Other patients at increased risk of hyperkalemia include those with severe adrenal insufficiency or treated concurrently with other drugs that cause or increase the risk of hyperkalemia
 
  <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-fb62b24f-b83d-4510-9e5d-4a48f8eb0317">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Patients with cardiac disease may be more susceptible to the effects of hyperkalemia.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Consider the amount of potassium from all sources when determining the dose of potassium phosphates injection and do not exceed the maximum age-appropriate recommended daily amount of potassium. In patients with moderate renal impairment (eGFR ≥30 mL/min/1.73 m
 
  <sup>2</sup>to &lt;60 mL/min/1.73 m
 
  <sup>2</sup>), start at the low end of the dose range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Use in Specific Populations (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-001a9f01-9249-421f-a4e8-02dcc60d5fcc">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>When administering potassium phosphates injection in intravenous fluids to correct hypophosphatemia, check the serum potassium concentration prior to administration. If the potassium concentration is 4 mEq/dL or more, do not administer potassium phosphates injection and use an alternative source of phosphorus
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>The maximum initial or single dose of potassium phosphates injection in intravenous fluids to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate of potassium through a peripheral venous catheter is 10 mEq/hour. Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240927"/>
                  </section>
               </component>
               <component>
                  <section ID="S-c34970fd-373b-4a43-bf37-38dddc161f80">
                     <id root="2f2fccc5-9ccc-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hyperphosphatemia and Hypocalcemia</title>
                     <text>
                        <paragraph>Hyperphosphatemia can occur with intravenous administration of potassium phosphates, especially in patients with renal impairment. Hyperphosphatemia can cause the formation of insoluble calcium phosphorus products with consequent hypocalcemia, neurological irritability with tetany, nephrocalcinosis with acute kidney injury and more rarely, cardiac irritability with arrhythmias.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Obtain serum calcium concentrations prior to administration and normalize the calcium before administering potassium phosphates injection. Potassium phosphates injection is contraindicated in patients with hyperphosphatemia and/or hypercalcemia
 
  <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>Monitor serum phosphorus and calcium concentrations during treatment with potassium phosphates injection
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
               <component>
                  <section ID="S-5bd07da3-03a8-4bde-8260-1a2782718118">
                     <id root="2f2fccc5-9ccd-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Aluminum Toxicity</title>
                     <text>
                        <paragraph>Potassium phosphates injection contains aluminum that may be toxic.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate containing solutions, which also contain aluminum.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Exposure to aluminum from potassium phosphates injection is no more than 0.6 mcg/kg/day when patients are administered the recommended dosage
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Description (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-0fb4d54d-4833-4d31-9577-4544a7d3e85a">11</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>When prescribing potassium phosphates injection for use in parenteral nutrition solutions containing other small volume parenteral products, the total daily patient exposure to aluminum from the admixture should be considered and maintained at no more than 5 mcg/kg/day
 
  <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="underline">
                              <linkHtml href="#S-67628c11-497b-4043-8969-f7b215936495">8.4</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240910"/>
                  </section>
               </component>
               <component>
                  <section ID="S-db40c10b-c739-459c-b631-d6b693ca1493">
                     <id root="2f2fccc5-9cce-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Hypomagnesemia</title>
                     <text>
                        <paragraph>Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section ID="S-db81a30d-d481-4bf5-b388-cfb7f91a0685">
                     <id root="2f2fccc5-9ccf-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Vein Damage and Thrombosis</title>
                     <text>
                        <paragraph>Potassium phosphates injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition. It is not for direct intravenous infusion. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral administration is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible and initiate appropriate medical treatment if thrombophlebitis develops.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>When administered peripherally in intravenous fluids to correct hypophosphatemia, a generally recommended maximum concentration is phosphorus 6.8 mmol/100 mL (potassium 10 mEq/100 mL)
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>
                        </paragraph>
                        <paragraph>Parenteral nutrition solutions with an osmolarity of 900 mOsmol/L or greater must be infused through a central catheter
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2f2fccc5-9cd0-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Laboratory Monitoring</title>
                     <text>
                        <paragraph>Monitor serum phosphorus, potassium, calcium and magnesium concentrations during treatment
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S-6bf58642-76fb-4033-beaf-478fb4061606">
               <id root="2f2fccc5-9cd1-27d6-e063-6294a90a55f9"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <paragraph> </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Aluminum Toxicity
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <content styleCode="underline">
                              <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                           </content>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hypomagnesemia
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <content styleCode="underline">
                              <linkHtml href="#S-db40c10b-c739-459c-b631-d6b693ca1493">5.6</linkHtml>
                           </content>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Vein Damage and Thrombosis
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <content styleCode="underline">
                              <linkHtml href="#S-db81a30d-d481-4bf5-b388-cfb7f91a0685">5.7</linkHtml>
                           </content>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
                  <paragraph> </paragraph>
                  <paragraph>The following adverse reactions in Table 5 have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered potassium phosphates. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="bold">TABLE 5: Adverse Reactions Reported in Clinical Studies or Postmarketing Reports with Intravenous Potassium Phosphates</content>
                  </paragraph>
                  <table width="100%">
                     <col width="50%" align="left" valign="middle"/>
                     <col width="50%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">System Organ Class</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Botrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">Adverse Reactions</content>
                              </paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Metabolism and Nutrition Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule Toprule" valign="top">
                              <paragraph>pulmonary embolism due to pulmonary vascular precipitates
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-0294bce5-bdcc-4561-9222-0a43de548eb4">5.2</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>, hyperkalemia
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>, hyperphosphatemia
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>, hypocalcemia
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>, hypovolemia, and osmotic diuresis
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Cardiac Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>hypotension, arrhythmia, heart block, cardiac arrest, bradycardia, chest pain, ECG changes
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-73dc1c12-6aaf-4223-8218-5af3789dbd57">5.1</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>, and edema
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>dyspnea
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-0294bce5-bdcc-4561-9222-0a43de548eb4">5.2</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Renal and Urinary Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury), decreased urine output, and transition to chronic kidney disease
     
      <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <content styleCode="underline">
                                       <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                                    </content>
                                 </content>
                                 <content styleCode="italics">)]</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>diarrhea, stomach pain</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Musculoskeletal and Connective Tissue Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>weakness</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="italics">Nervous System Disorders</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Rrule" valign="top">
                              <paragraph>confusion, lethargy, paralysis, paresthesia</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20240320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions include hyperkalemia, hyperphosphatemia, hypocalcemia, and hypomagnesemia. (
 
    <content styleCode="underline">
                              <linkHtml href="#S-6bf58642-76fb-4033-beaf-478fb4061606">6</linkHtml>
                           </content>)

   </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cd2-27d6-e063-6294a90a55f9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240320"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use of Other Medications that Increase Potassium</content>: Avoid use in patients receiving such products. If use cannot be avoided, closely monitor serum potassium concentrations. (
 
    <content styleCode="underline">
                              <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                           </content>,
 
    <content styleCode="underline">
                              <linkHtml href="#S-fb62b24f-b83d-4510-9e5d-4a48f8eb0317">7.1</linkHtml>
                           </content>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S-fb62b24f-b83d-4510-9e5d-4a48f8eb0317">
                     <id root="2f2fccc5-9cd3-27d6-e063-6294a90a55f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Other Products that Increase Serum Potassium</title>
                     <text>
                        <paragraph>Administration of potassium phosphates injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia
 
  <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>. Avoid use of potassium phosphates injection in patients receiving such products. If use cannot be avoided, closely monitor serum potassium concentrations
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cd4-27d6-e063-6294a90a55f9"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20241008"/>
               <component>
                  <section>
                     <id root="2f2fccc5-9cd5-27d6-e063-6294a90a55f9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with potassium phosphates injection.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease-associated Maternal and/or Embryo-Fetal Risk</content>
                        </paragraph>
                        <paragraph>Phosphorus is an essential mineral element. Parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2f2fccc5-9cd6-27d6-e063-6294a90a55f9"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Phosphorus and potassium are present in human milk. Administration of the recommended dose of potassium phosphates injection is not expected to cause harm to a breastfed infant. There is no information on the effects of potassium phosphates on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for potassium phosphates injection and any potential adverse effects on the breastfed child from potassium phosphates injection or from underlying maternal condition.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section ID="S-67628c11-497b-4043-8969-f7b215936495">
                     <id root="2f2fccc5-9cd7-27d6-e063-6294a90a55f9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of potassium phosphates injection have been established in pediatric patients as a source of phosphorus:</paragraph>
                        <paragraph> </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated.</item>
                           <item>for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.</item>
                        </list>
                        <paragraph> </paragraph>
                        <paragraph>Because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with potassium phosphates injection may be at higher risk of aluminum toxicity.
 
  <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240910"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2f2fccc5-9cd8-27d6-e063-6294a90a55f9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In general, dose selection of potassium phosphates injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. It may be useful to monitor renal function during treatment
 
  <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-001a9f01-9249-421f-a4e8-02dcc60d5fcc">8.6</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
               <component>
                  <section ID="S-001a9f01-9249-421f-a4e8-02dcc60d5fcc">
                     <id root="2f2fccc5-9cd9-27d6-e063-6294a90a55f9"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to potassium phosphates injection may be greater in patients with impaired renal function
 
  <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Potassium phosphates injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m
 
  <sup>2</sup>) or end stage renal disease
 
  <content styleCode="italics">[see Contraindications (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-8385e99f-76fd-4089-890c-4e88f26a7f5d">4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m
 
  <sup>2</sup>to &lt; 60 mL/min/1.73 m
 
  <sup>2</sup>), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-784b8156-9e6d-4bb0-a47b-d4df152bc237">2.2</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">,</content>
                           <content styleCode="italics">
                              <content styleCode="underline">
                                 <linkHtml href="#S-6bc9d134-fd55-40b7-b95f-1c19aa3ebe47">2.4</linkHtml>
                              </content>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240320"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S-54791af5-2013-4580-aec1-67ae6ad5bd1c">
               <id root="2f2fccc5-9cda-27d6-e063-6294a90a55f9"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperphosphatemia</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Administration of excessive doses of intravenous potassium phosphates in intravenous fluids as a single dose ranging from approximately 50 to 270 mmol phosphorus and/or at rapid infusion rates (over 1 to 3 hours) has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia, seizures, and tetany.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Hyperphosphatemia is particularly a risk in patients with renal failure. Hyperphosphatemia leads in turn to hypocalcemia, which may be severe, and to ectopic calcification, particularly in patients with initial hypercalcemia. Tissue calcification may cause hypotension and organ damage and result in acute renal failure.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperkalemia</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Excessive administration of phosphates given as potassium salts may also cause hyperkalemia. Manifestations of hyperkalemia include:</paragraph>
                  <paragraph> </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Disturbances in cardiac conduction and arrhythmias, including bradycardia, heart block, asystole, ventricular tachycardia, ventricular fibrillation</item>
                     <item>Hypotension</item>
                     <item>Muscle weakness including paresthesia, muscular and respiratory paralysis</item>
                  </list>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="underline">Management</content>
                  </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>In the event of overdosage, discontinue infusions containing potassium phosphates immediately and institute general supportive measures, including ECG monitoring, laboratory monitoring, and correction of serum electrolyte concentrations, especially potassium, phosphorus, calcium, and magnesium.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20240319"/>
            </section>
         </component>
         <component>
            <section ID="S-0fb4d54d-4833-4d31-9577-4544a7d3e85a">
               <id root="2f2fccc5-9cdb-27d6-e063-6294a90a55f9"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph> </paragraph>
                  <paragraph>Potassium phosphates injection, USP, a phosphorus replacement product containing phosphorus 3 mmol/mL and potassium 4.4 mEq/mL. It is a sterile, non-pyrogenic, concentrated solution containing a mixture of monobasic potassium phosphate and dibasic potassium phosphate in water for injection. It is supplied as a 5 mL and 15 mL single-dose vials and a 50 mL Pharmacy Bulk Package vial.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Monobasic Potassium Phosphate is chemically designated KH
 
  <sub>2</sub>PO
 
  <sub>4</sub>, molecular weight 136.09, white or colorless crystals or crystalline powder freely soluble in water.

 </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Dibasic Potassium Phosphate is chemically designated K
 
  <sub>2</sub>HPO
 
  <sub>4</sub>, molecular weight 174.18, colorless to white granular powder freely soluble in water.

 </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Each mL contains 224 mg of monobasic potassium phosphate and 236 mg of dibasic potassium phosphate.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Each mL contains 3 mmol phosphorus (equivalent to 93 mg phosphorus) and 4.4 mEq potassium (equivalent to 170 mg of potassium). Note: 1 mmol of phosphorus is equal to 1 mmol phosphate. The pH is 6.0 to 7.0.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>This product contains no more than 900 mcg/L of aluminum
 
  <content styleCode="italics">[</content>see
 
  <content styleCode="italics">Warnings and Precautions (5.5)]</content>.

 </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>The osmolarity is 7.4 mOsmol/mL (calc).</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>The solution is administered after dilution or admixing by the intravenous route.</paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20240910"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cdc-27d6-e063-6294a90a55f9"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240319"/>
               <component>
                  <section>
                     <id root="2f2fccc5-9cdd-27d6-e063-6294a90a55f9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph> </paragraph>
                        <paragraph>Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis and bone mineralization.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2f2fccc5-9cde-27d6-e063-6294a90a55f9"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Approximately 85% of serum phosphates is free and ultra-filterable and 15% is protein-bound.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph>Intravenously infused phosphates not taken up by the tissues are excreted almost entirely in the urine. Serum phosphorus is believed to be filterable by the renal glomeruli and the major portion of filtered phosphorus (greater than 80%) is actively reabsorbed by the tubules.</paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20240319"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9cdf-27d6-e063-6294a90a55f9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Potassium phosphates injection, USP is a clear and colorless solution free from visible particulates supplied as phosphorus 3 mmol/mL and potassium 4.4 mEq/mL as shown:</paragraph>
                  <paragraph> </paragraph>
                  <table width="100%">
                     <col width="34%" align="left" valign="middle"/>
                     <col width="33%" align="left" valign="middle"/>
                     <col width="33%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <td align="center">
                              <paragraph>Unit of Sale</paragraph>
                           </td>
                           <td align="center">
                              <paragraph>Strength</paragraph>
                           </td>
                           <td align="center">
                              <paragraph>Each</paragraph>
                           </td>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>NDC 69097-078-97</paragraph>
                              <paragraph>Carton containing 25 units</paragraph>
                           </td>
                           <td styleCode="Toprule Rrule Botrule" valign="top">
                              <paragraph>Phosphorus 15 mmol/5 mL and Potassium 22 mEq/5 mL</paragraph>
                           </td>
                           <td styleCode="Toprule Rrule Botrule" valign="top">
                              <paragraph>NDC 69097-078-67</paragraph>
                              <paragraph>5 mL single dose, plastic vial</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule" valign="top">
                              <paragraph>NDC 69097-077-97</paragraph>
                              <paragraph>Carton containing 25 units</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule" valign="top">
                              <paragraph>Phosphorus 45 mmol/15 mL and Potassium 66 mEq/15 mL</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule" valign="top">
                              <paragraph>NDC 69097-077-67</paragraph>
                              <paragraph>15 mL single dose, plastic vial</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule" valign="top">
                              <paragraph>NDC 69097-055-97</paragraph>
                              <paragraph>Carton containing 25 units</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule" valign="top">
                              <paragraph>Phosphorus 150 mmol/50 mL and Potassium 220 mEq/50 mL</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule" valign="top">
                              <paragraph>NDC 69097-055-67</paragraph>
                              <paragraph>50 mL fill Pharmacy Bulk Package, plastic vial.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph> </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Pharmacy Bulk Package vial: Discard within 4 hours of initial entry
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="underline">
                        <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.

 </paragraph>
                  <paragraph>For storage of admixed solution
 
  <content styleCode="italics">see Dosage and Administration</content>
                     <content styleCode="underline">
                        <linkHtml href="#S-cb6756f5-df6a-4baf-862a-70734970cc84">2.1</linkHtml>
                     </content>
                     <content styleCode="italics">,</content>
                     <content styleCode="underline">
                        <linkHtml href="#S-4ce8ab90-705d-44fe-b839-eb8ecdd7a088">2.3</linkHtml>
                     </content>
                     <content styleCode="italics">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240927"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9ce0-27d6-e063-6294a90a55f9"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Inform patients, caregivers or home healthcare providers of the following risks of potassium phosphates injection:</paragraph>
                  <paragraph> </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Serious Cardiac Adverse Reactions with Undiluted, Bolus or Rapid Intravenous Administration
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-73dc1c12-6aaf-4223-8218-5af3789dbd57">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Pulmonary Embolism due to Pulmonary Vascular Precipitates
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-0294bce5-bdcc-4561-9222-0a43de548eb4">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hyperkalemia
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-ace24d3e-5fb3-4f4d-83f1-6e2679247f40">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hyperphosphatemia and Hypocalcemia
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-c34970fd-373b-4a43-bf37-38dddc161f80">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Aluminum toxicity
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-5bd07da3-03a8-4bde-8260-1a2782718118">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hypomagnesemia
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-db40c10b-c739-459c-b631-d6b693ca1493">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Vein Damage and Thrombosis
  
   <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="underline">
                           <linkHtml href="#S-db81a30d-d481-4bf5-b388-cfb7f91a0685">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>Cipla Ltd., India</paragraph>
                  <paragraph>At M/s. Abryl Laboratories Private Limited</paragraph>
                  <paragraph>Village Bhagwanpur, Tehsil Dera Bassi,</paragraph>
                  <paragraph>District Sahibzada Ajit Singh Nagar,</paragraph>
                  <paragraph>Punjab 140507, India (IND) </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Cipla USA,</paragraph>
                  <paragraph>Inc. 10 Independence Boulevard,</paragraph>
                  <paragraph>Suite 300 Warren,</paragraph>
                  <paragraph>NJ 07059</paragraph>
                  <paragraph> </paragraph>
                  <paragraph>Revised: 10/2024</paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20241009"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2f2fccc5-9ce1-27d6-e063-6294a90a55f9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 69097-078-67 Vial Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 15 mmol/5 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 22 mEq/5 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>5 mL Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <paragraph> 
 
  <renderMultiMedia referencedObject="MM101"/>
                  </paragraph>
                  <paragraph> </paragraph>
                  <paragraph> </paragraph>
                  <paragraph>NDC 69097-078-97 Carton Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 15 mmol/5 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 22 mEq/5 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>25 x 5 mL Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <renderMultiMedia referencedObject="MM102"/>
                  <paragraph> </paragraph>
                  <paragraph>NDC 69097-077-67 Vial Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 45 mmol/15 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 66 mEq/15 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>15 mL Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <renderMultiMedia referencedObject="MM103"/>
                  <paragraph> </paragraph>
                  <paragraph>NDC 69097-077-97 Carton Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 45 mmol/15 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 66 mEq/15 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>25 x 15 mL Single-Dose Vial</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <renderMultiMedia referencedObject="MM104"/>
                  <paragraph> </paragraph>
                  <paragraph>NDC 69097-055-67 Bulk Package Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 150 mmol/50 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 220 mEq/50 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>Pharmacy Bulk Package – Not for Direct Infusion</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>50 mL</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <renderMultiMedia referencedObject="MM105"/>
                  <paragraph>NDC 69097-055-97 Carton Label Rx only</paragraph>
                  <paragraph>Potassium Phosphates Injection, USP</paragraph>
                  <paragraph>Phosphorus 150 mmol/50 mL (3 mmol/mL)</paragraph>
                  <paragraph>Potassium 220 mEq/50 mL (4.4 mEq/mL)</paragraph>
                  <paragraph>Pharmacy Bulk Package – Not for Direct Infusion</paragraph>
                  <paragraph>CAUTION: MUST BE DILUTED</paragraph>
                  <paragraph>For Intravenous use only</paragraph>
                  <paragraph>25 x 50 mL</paragraph>
                  <paragraph>Discard Unused Portion</paragraph>
                  <renderMultiMedia referencedObject="MM106"/>
                  <paragraph> </paragraph>
               </text>
               <effectiveTime value="20241015"/>
               <component>
                  <observationMedia ID="MM101">
                     <text>vial-5ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vial-5ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM102">
                     <text>carton-5ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-5ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM103">
                     <text>vial-15ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vial-15ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM104">
                     <text>carton-15ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-15ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM105">
                     <text>vial-50ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="vial-50ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM106">
                     <text>carton-50ml</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-50ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>